Yazar "Uysal, Mükremin" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Eccrine porocarcinoma: A case report and literature review
    (2013) Arslan, Deniz; Tatlı, Ali Murat; Kaplan, Muhammet Ali; Uysal, Mükremin
    Ekrin porokarsinoma ter bezlerinin nadir görülen bir tümörüdür. Daha çok yaşlılarda gözlenir ve alt ekstremiteleri tutma eğilimindedir. Ana tedavi yöntemi cerrahi eksizyondur ve lokal ve uzak nüksler gösterebilir. Kemoterapi ve radyoterapinin etkisi çelişkilidir. Biz burada 90 yaşında kadın hastada aksillar bölgede lokalize ekrin porokarsinoma vakasını mevcut literatür eşliğinde sunduk
  • Küçük Resim
    Öğe
    Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study
    (Taylor & Francis, 2022) Bilici, Ahmet; Uysal, Mükremin; Menekşe, Serkan; Akın, Semih; Yıldız, Fatih; Turan, Merve; Kaplan, Muhammet Ali
    Purpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.